Hemato-oncology
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522. Published online April 14, 2017
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based t..
|